Bayesian Capital Management, LP Neurocrine Biosciences Inc Transaction History

Bayesian Capital Management, LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $495,520 - $546,212	3,800 Added 43.92%	12,453 $1.72 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $917,823 - $1.15 Million	8,653 New	8,653 $1.14 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $373,520 - $444,710	3,500 New	3,500 $418,000
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $660,358 - $871,909	-8,713 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $631,256 - $826,079	8,713 New	8,713 $817,000
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $399,786 - $498,318	-4,600 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $442,336 - $621,690	4,600 New	4,600 $442,000
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $1.07 Million - $1.61 Million	-14,184 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $1.23 Million - $1.68 Million	14,184 New	14,184 $1.53 Million
Q4 2018 Feb 13, 2019	SELL	$68.32 - $124.36 $212,406 - $386,635	-3,109 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $307,417 - $391,267	3,109 New	3,109 $382,000
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $860,479 - $1.05 Million	-11,340 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$58.53 - $77.59 $402,335 - $533,353	6,874 Added 153.92%	11,340 $880,000
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $214,234 - $273,676	4,466	4,466 $274,000

641

95.3M

661K

227K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.